Dwight Gary Gilliland

Dwight Gary Gilliland's AcademicInfluence.com Rankings

Philosophy

#5937

World Rank

#8875

Historical Rank

Logic

#3140

World Rank

#4257

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Dwight Gary Gilliland's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Dwight Gary Gilliland Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dwight Gary Gilliland's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005) (2933)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 (2009) (2300)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. (2003) (1709)
FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress (2007) (1564)
The roles of FLT3 in hematopoiesis and leukemia. (2002) (1478)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. (2005) (1471)
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 (2006) (1433)
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia (2006) (1325)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. (2007) (1251)
FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis (2007) (1038)
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. (2006) (1026)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
Activating mutations in ALK provide a therapeutic target in neuroblastoma (2008) (830)
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. (2004) (734)
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. (2009) (701)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005) (696)
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth (2009) (681)
Drug therapy for acute myeloid leukemia. (2005) (668)
Leukaemia stem cells and the evolution of cancer-stem-cell research (2005) (632)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. (2002) (613)
Core-binding factors in haematopoiesis and leukaemia (2002) (589)
Genetics of myeloid leukemias. (2003) (580)
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. (1997) (579)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders (2007) (556)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells (2009) (546)
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. (2002) (542)
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. (2013) (534)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. (2006) (494)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. (2005) (492)
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. (2004) (481)
The leukemic stem cell niche: current concepts and therapeutic opportunities. (2009) (468)
Direct inhibition of the NOTCH transcription factor complex (2009) (465)
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. (2010) (464)
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia (2004) (432)
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase (2007) (432)
Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation (2004) (415)
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. (2011) (382)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. (2005) (377)
Genetics of myeloid malignancies: pathogenetic and clinical implications. (2005) (373)
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. (2003) (373)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. (2003) (372)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. (2007) (369)
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. (2000) (341)
Activating alleles of JAK3 in acute megakaryoblastic leukemia. (2006) (333)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms (2009) (331)
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia (2010) (331)
The molecular basis of leukemia. (2004) (330)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. (2014) (329)
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. (2010) (320)
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). (2002) (319)
Direct inhibition of the NOTCH transcription factor complex (2010) (308)
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. (2007) (302)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
Yolk sac angiogenic defect and intra‐embryonic apoptosis in mice lacking the Ets‐related factor TEL (1997) (297)
PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model (2002) (293)
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. (2004) (283)
Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes (1998) (280)
Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. (1991) (270)
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. (2005) (269)
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. (2010) (265)
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. (2007) (264)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. (2004) (263)
AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias (2011) (251)
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. (1980) (250)
The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways (1996) (249)
The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management (2004) (249)
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. (2005) (249)
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. (2005) (248)
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis (2008) (246)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. (2005) (241)
Role of FLT3 in leukemia. (2002) (235)
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. (2003) (234)
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. (2003) (221)
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. (2007) (215)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations (2006) (213)
Molecular genetics of human leukemias: new insights into therapy. (2002) (213)
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 (2002) (209)
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. (2002) (205)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. (2007) (203)
Prediction of Resistance to Small Molecule FLT3 Inhibitors (2004) (192)
Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation (2001) (191)
Focus on acute leukemias. (2002) (188)
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. (2010) (180)
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. (2009) (178)
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. (2004) (172)
Molecular genetics of acute myeloid leukaemia. (2001) (168)
Oncogenes in Myeloproliferative Disorders (2007) (167)
Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. (2015) (166)
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. (2012) (164)
Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor β Receptor (PDGFβR) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2) (1998) (163)
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. (2006) (157)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. (2008) (156)
Differential niche and Wnt requirements during acute myeloid leukemia progression. (2011) (154)
Jak2: normal function and role in hematopoietic disorders. (2007) (152)
Deregulation of signaling pathways in acute myeloid leukemia. (2008) (152)
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. (2006) (149)
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. (2007) (147)
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy (2013) (143)
Notch signaling specifies megakaryocyte development from hematopoietic stem cells. (2008) (143)
Cancer biology: Summing up cancer stem cells (2005) (140)
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. (2008) (136)
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). (2001) (135)
Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL (2012) (133)
The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients. (2006) (131)
Unifying mechanism for different fibrotic diseases (2017) (129)
Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic (1980) (128)
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. (2005) (125)
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. (1998) (125)
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. (2009) (121)
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. (2003) (121)
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. (2006) (121)
The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. (2001) (121)
Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. (2000) (120)
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. (2005) (120)
Structural and numerical variation of FLT3/ITD in pediatric AML. (2008) (118)
Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent (2006) (118)
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. (2003) (118)
Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice (2000) (117)
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. (2009) (116)
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. (2004) (107)
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. (2004) (107)
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. (2011) (107)
Drug development and clinical trials—the path to an approved cancer drug (2012) (105)
Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 (2002) (104)
Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. (2013) (102)
Hematopoietic Stem Cell Defects in Mice with Deficiency of Fancd2 or Usp1 (2010) (102)
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. (2008) (100)
The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. (2010) (100)
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. (2007) (99)
TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor (1999) (99)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies (2005) (98)
Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome (2000) (97)
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. (2009) (96)
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. (2004) (96)
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). (1998) (96)
A role for JAK2 mutations in myeloproliferative diseases. (2008) (95)
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. (2004) (94)
Comprehensive evaluation of isoprenoid biosynthesis regulation in Saccharomyces cerevisiae utilizing the Genome Reporter Matrix. (1999) (88)
Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. (2009) (86)
PML–RARα initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors (2009) (86)
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model (2005) (85)
Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model (2006) (85)
Myeloproliferative disorders. (2008) (83)
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. (2004) (82)
Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor β Receptor Fusion Protein* (1999) (77)
Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes (2007) (76)
The role of signal transducer and activator of transcription factors in leukemogenesis. (2004) (74)
The FIP1L1-PDGFR&agr; kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia (2004) (72)
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. (2009) (72)
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. (2006) (70)
Ott1(Rbm15) has pleiotropic roles in hematopoietic development (2007) (70)
A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (2008) (69)
Hematologic malignancies. (2001) (69)
JAK2 in Myeloproliferative Disorders Is Not Just Another Kinase (2005) (68)
Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. (2008) (68)
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. (2004) (68)
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. (2006) (68)
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. (2011) (65)
Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. (2006) (64)
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. (2000) (62)
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. (2006) (62)
The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia (2005) (62)
The JAK 2 V 617 F activating tyrosine kinase mutation is an infrequent event in both “ atypical ” myeloproliferative disorders and myelodysplastic syndromes (2005) (61)
The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. (2001) (60)
Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxin. (1978) (59)
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. (2011) (57)
Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. (2002) (57)
Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease (2006) (56)
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. (2007) (53)
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. (2008) (53)
JAK-2 mutations and their relevance to myeloproliferative disease (2007) (53)
A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. (2007) (52)
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. (2006) (52)
A progenitor cell origin of myeloid malignancies (2009) (52)
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. (2002) (52)
Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. (1998) (52)
Leukemia stem cells. (2010) (51)
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. (2007) (47)
Molecular genetics of human leukemia. (1998) (46)
A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. (2009) (45)
Ott1 (Rbm15) Is Essential for Placental Vascular Branching Morphogenesis and Embryonic Development of the Heart and Spleen (2008) (43)
Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. (2004) (42)
Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. (2005) (42)
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. (2004) (42)
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. (2012) (41)
Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia. (2004) (40)
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. (2002) (38)
Clonality in myeloproliferative disorders. (1992) (36)
STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. (2013) (35)
Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. (2006) (35)
The diverse role of the ETS family of transcription factors in cancer. (2001) (34)
Oncogenic K-ras in Mouse Models of Myeloproliferative Disease and Acute Myeloid Leukemia (2004) (34)
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. (2003) (33)
Molecular biology of acute myeloid leukemia. (1997) (32)
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. (1999) (31)
The FIP 1 L 1-PDGFR fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis , classification , and management (2004) (28)
Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. (2006) (28)
A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis (2008) (28)
EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head (2005) (27)
A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells. (2012) (27)
Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling. (2020) (24)
Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome. (2009) (22)
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. (2001) (21)
Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis (2010) (19)
Isolation of early hematopoietic stem cells from murine yolk sac and AGM. (2008) (18)
A radical bailout strategy for cancer stem cells. (2009) (18)
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice. (2015) (15)
A model system involving anti-concanavalin A for antibody targeting of diphtheria toxin fragment A1. (1980) (15)
Clonality in acquired hematologic disorders. (1991) (15)
Activation of FIP 1 L 1-PDGFR requires disruption of the juxtamembrane domain of PDGFR and is FIP 1 L 1-independent (2006) (15)
Positive and negative regulatory roles of the WW-like domain in TEL-PDGFβR transformation (2004) (15)
Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden (2010) (14)
Structure-activity relationships in diphtheria toxin and exotoxin A from Pseudomonas aeruginosa. (1979) (13)
Targeted therapies in myeloid leukemias. (2004) (12)
The small molecule tyrosine kinase inhibitor AMN 107 inhibits TEL-PDGFR and FIP 1 L 1-PDGFR in vitro and in vivo (2005) (12)
Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. (2004) (10)
The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. (2022) (10)
Advances in Brief Prediction of Resistance to Small Molecule FLT 3 Inhibitors : Implications for Molecularly Targeted Therapy of Acute Leukemia (2004) (10)
A hybrid toxin containing fragment A from diphtheria toxin linked to the B protomer of cholera toxin. (1980) (9)
JAK2 V617F Mutation in Essential Thrombocythemia: Clinical Associations and Long-Term Prognostic Relevance. (2005) (8)
CVD of BaF2 with new stable and volatile complexes of barium(II) (1992) (8)
Murky waters for MRD detection in AML: flightyFLT3/ITDs (2002) (8)
Characterization of hybrid molecules containing fragment A from diphtheria toxin linked to concanavalin A or the binding subunit of ricin toxin. (1981) (8)
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesis. (2006) (8)
The Clinical and PRV-1 Expression Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2 V617F in Polycythemia Vera. (2005) (7)
PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation. (2003) (7)
Going with the flow: JAK-STAT signaling in JMML. (2008) (7)
Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations. (2007) (6)
Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia. (2006) (6)
Mechanisms of GVL Against a Murine Blast Crisis CML. (2006) (6)
KIT with D 816 mutations cooperates with CBFB-MYH 11 for leukemogenesis in mice (2012) (5)
Molecular transformation from committed progenitor to leukemia stem cell initiated by MLL-AF 9 (2006) (5)
Mtor Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis (2011) (5)
Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML (2004) (5)
PU.1 Is a Critical Downstream Target of AML1. (2004) (4)
The Genetics of Acute Myeloid Leukemias (2007) (4)
Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor (1999) (4)
Fusion of NUP214 to ABL1 on amplified extrachromosomal elements in T-ALL. (2004) (4)
Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma (2001) (4)
FLT3 Inhibitors in the Treatment of AML. (2004) (4)
Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context (2016) (4)
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective (2006) (4)
AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models. (2004) (3)
Proteolytic Processing in Development and Leukemogenesis (2003) (3)
CHIMERIC TOXINS CONTAINING FRAGMENT A FROM DIPHTHERIA TOXIN (1981) (3)
Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation. (2004) (3)
Small Molecule Therapeutics Preclinical Evaluation of the WEE 1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy (2013) (3)
AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase (2005) (3)
TEL/PDGFβR fusion protein activates STAT1 and STAT5 (2000) (3)
AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias (2011) (3)
CEBPA dosage in leukemogenesis (2006) (2)
Characterization of Distinct Molecular Signatures in Myeloproliferative Diseases with the JAK2V617F Mutation and Wild Type JAK2. (2005) (2)
[The OTT-MAL fusion oncogene: another Notch in megakaryoblastic leukemia]. (2009) (2)
Comparative Analysis of the Constitutively Active MPLW515L and JAK2V617F Alleles in a Murine Bone Marrow Transplant Model of Myeloproliferative Disease. (2006) (2)
Erratum: PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis (2008) (2)
FoxO Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress. (2006) (2)
Mechanisms of Activation of the FIP1L1-PDGFRα Fusion Kinase. (2004) (2)
Fatal myeloproliferation, induced in mice by TEL/PDGF b R expression, depends on PDGF b R tyrosines 579/581 (2000) (2)
A Regulatory Network Between Notch and AKT Signaling Pathways Differentially Controls Megakaryocyte Development From Hematopoietic Stem or Committed Progenitor Cells. (2009) (2)
The JAK2 V617F Tyrosine Kinase Mutation in Myelofibrosis with Myeloid Metaplasia: Clinical Correlates and Prognostic Relevance in 157 Patients. (2005) (2)
Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling. (2004) (2)
C-KIT with D816Y/V Mutations Cooperate with CBFB-MYH11 to Accelerate Leukemogenesis in Mice. (2009) (2)
Response: To be skewed or not to be? This is no longer the question (2009) (1)
Cdx 4 Is Dispensable for Murine Adult Hematopoietic Stem Cells but Promotes MLL-AF 9-Mediated Leukemogenesis (2010) (1)
STAT 5 is crucial to maintain leukemic stem cells in acute myeloid leukemias induced by MOZ-TIF 2 (2012) (1)
Fatigue, the Un-Addressed Curse of Myeloproliferative Diseases (MPD): Results of an International Internet Based QOL Survey of 830 MPD Patients. (2005) (1)
myeloproliferative neoplasms negative - leukemic transformation of Philadelphia chromosome Prevalence and prognostic impact of allelic imbalances associated with (2011) (1)
PKC412 Effectively Inhibits Constitutively Activated FGFR3 Mutants in Murine Leukemia Models and t(4;14) Myeloma Cell Lines. (2004) (1)
K-Ras G12D –induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to (cid:1) -secretase inhibitors (2008) (1)
EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L (2008) (1)
Leukemogenic FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitor Cells in a Murine Model of Chronic Myelomonocytic Leukemia. (2007) (1)
respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3 (2013) (1)
Tumor and Stem Cell Biology STAT 5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF 2 (2012) (1)
Global Effects of BCR/ABL and TEL/PDGFRβ Expression on the Proteome and Phosphoproteome (2005) (1)
Leukemic Promyelocytes Possess Self-Renewal Capacity and Leukemia Stem Cell Properties in a Mouse Model of Acute Promyelocytic Leukemia. (2007) (1)
Integrated Immunological Analysis of the Bone Marrow Tumor Microenvironment in Myeloproliferative Neoplasms to Determine Potential Efficacy of Immune Checkpoint Blockade (2015) (0)
An ENU Mutagenesis Screen of FLT3-ITD Knock-in Mice Identifies Novel Gene Mutations That Lead to an Exacerbated Myeloproliferative Neoplasm (2014) (0)
Integrative Analysis of Genomic Aberration and Gene Expression Suggests That MPD with Loss of Heterozygosity or Gain of Chromosome 9 Represents a Distinct Entity (2008) (0)
NFIB: A Gene Consistently Upregulated in MPD and Frequently Co-Amplified with JAK2V617F Augments Growth of Erythropoietin Dependent Cells (2008) (0)
Creating a National Cohort of Myeloproliferative Disorders Using the Internet: A Feasibility Study. (2004) (0)
An ENU Mutagenesis Screen to Identify Genes Involved in the Induction of FLT3-ITD Positive Acute Myeloid Leukemia (2011) (0)
A look back: Results from 1 year of routine clinical testing of both hematologic and solid tumors using two targeted next-generation sequencing (NGS) panels. (2014) (0)
Leukemia Stem Cells Are Resistant to In Vivo, Cell Non-Autonomous Wnt Inhibition. (2009) (0)
The Role of Forkhead Transcription Factors FoxO1, FoxO3 and FoxO4 in Hematopoiesis and Leukemogenesis. (2005) (0)
Use of FLT3 inhibitors in leukemia: a wrench in the activation loop (2003) (0)
FLT3 Tyrosine Kinase in AML Identification and Characterization of a Novel Activating Mutation of the (2012) (0)
Lineage Instruction by Oncogenic Tyrosine Kinase Fusions. (2005) (0)
Secondary Myelodysplasia/Acute Myelogenous Leukemia: Assessment of Risk (2010) (0)
Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders. (2006) (0)
Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. (2006) (0)
Hedgehog Signaling Is Dispensable for Adult Murine Hematopoiesis and Leukemogenesis. (2008) (0)
pathway activation in myeloproliferative neoplasm pathogenesis Integrated genomic analysis illustrates the central role of JAK-STAT (2014) (0)
of the Myc and Pim proto-oncogenes requires a functional FERM domain for transformation and for expression The Jak2V617F oncogene associated with myeloproliferative diseases (2013) (0)
Leukemia stem cells occupy niches that are physically distinct and independent of the normal constraints that apply to hematopoietic stem cells (2010) (0)
and M7 Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, (2011) (0)
Coordinate loss of a microRNAand protein-coding gene cooperate in the pathogenesis of 5qsyndrome (2016) (0)
Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias (2011) (0)
High-Throughput RNA Interference Screening Identifies Synthetic Lethality Between Oncogenic KRAS Dependency and Suppression of STK33 (2008) (0)
Conversation: Qiufu Ma and Colleagues Identify Runx1 Gene That May Control Neuropathic Pain (2006) (0)
Juxtamembrane Domain Truncation Is Sufficient for Activation of the FIP1L1-PDGFRα and ETV6-PDGFRβ Fusion Kinases. (2005) (0)
Abstract #5608: Synthetic lethal interaction between oncogenic KRAS dependency and suppression of STK33 in human cancer cells (2009) (0)
Development of a Myeloproliferative Disease or a T Cell Lymphoblastic Leukemia in a Murine Bone Marrow Transplant Model of NUP214-ABL1. (2006) (0)
Acute Myeloid Leukemias (2006) (0)
acute lymphoblastic The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic (2005) (0)
Constitutively activated FGFR3 mutants signal through PLCγ- dependent and-independent pathways for hematopoietic transformation. Running title: Systematic mutational analysis of autophosphorylated tyrosine residues (2005) (0)
Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes (2008) (0)
The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stem Cells. (2005) (0)
myeloid leukemias induced by MOZ-TIF 2 STAT 5 is crucial to maintain leukemic stem cells in acute (2012) (0)
Ott1 (Rbm15) Is Required for the Large to Small Pre B-Cell Transition (2008) (0)
The TEL / PDGF b R fusion in chronic myelomonocytic leukemia signals through STAT 5-dependent and STAT 5-independent pathways (2001) (0)
35. A Murine Bone Marrow Transplantation Model for TEL/PDGFβR Induced Myeloproliferative Disease: Requirement for Tyrosines 579/581 of PDGFβR (2000) (0)
STAT5 is crucial to maintain leukemic stem cells in acute myeloid leukemias induced by MOZ-TIF2 (2012) (0)
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5 q-syndrome RUNNING TITLE : COOPERATIVE LOSS OF MIR-145 AND RPS 14 IN 5 Q-MDS (2011) (0)
Notch Signaling Induces Megakaryocytic Cell Fate. (2007) (0)
The p110alpha and p110delta Isoforms of PI3 Kinase Are Dispensable for Hematopoietic Stem Cell Self-Renewal but Have Redundant Roles in B Cell Differentiation. (2012) (0)
Abstract #841: Targeted disruption of the Notch transcription factor complex in vitro and in vivo (2009) (0)
myelodysplastic syndromes event in both ''atypical'' myeloproliferative disorders and The JAK2 V617F activating tyrosine kinase mutation is an infrequent (2013) (0)
PKC 412 FLT3 inhibitor therapy in AML (2004) (0)
Runx1 Is Required for Notch-Induced Specification of Megakaryocyte Development from Early Hematopoietic Stem and Progenitor Cells (2008) (0)
leukemia or chronic lymphocytic leukemia leukemia and acute myeloid leukemia, but not in acute lymphoblastic The JAK2V617F activating mutation occurs in chronic myelomonocytic (2013) (0)
FOXO3a Regulates Survival and Proliferative Signaling Through Modulation of The NPM-ALK Fusion Kinase of Anaplastic Large Cell Lymphoma (2013) (0)
Systematic Genomic Screen for Tyrosine Kinase Mutations in CLL. (2007) (0)
OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia (2008) (0)
Your health in the 21st century. Do stem cells cause cancer? (2005) (0)
Promise and challenge of molecularly targeted therapy in hematologic malignancy (2002) (0)
for myelofibrosis research and treatment (IWG-MRT) response in myelofibrosis with myeloid metaplasia: On behalf of the IWG International Working Group (IWG) consensus criteria for treatment (2013) (0)
mutations in myeloid leukemia patients High-throughput sequencing screen reveals novel, transforming RAS (2013) (0)
Ott1(Rbm15) Is Essential for Pre-B Differentiation and Has an Inhibitory Role in Myeloid and Megakaryocytic Lineages. (2006) (0)
Transforming properties of TEL/JAK2 fusion proteins in hematopoietic cells. (1997) (0)
positive chronic eosinophilic leukemia - The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA (2013) (0)
Cdx4 Is Dispensable for Murine Hematopoiesis and MLL-AF9 Mediated Leukemogenesis. (2008) (0)
MPL W515L/K and JAK2 V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence. (2006) (0)
and -independent pathways for hematopoietic transformation -dependent γ Constitutively activated FGFR3 mutants signal through PLC (2013) (0)
The p110α Catalytic Isoform of PI3 Kinase Is Important for Erythropoiesis, but Has a Minimal Role in Hematopoietic Stem Cell Self-Renewal. (2009) (0)
Vascular Branching Morphogenesis of the Placenta Requires Expression of Ott1(Rbm15) in the Trophoblast Compartment. (2008) (0)
Abstract 3106: Intestinal mesenchymal fibroblasts promote early epithelial tumorigenesis through activation of integrin beta4 and receptor tyrosine kinases, bypassing common mutational mechanisms (2011) (0)
Hematopoietic Stem Cell Defects in Novel Fanconi Anemia Mouse Models (2008) (0)
Our results indicate that the JAK2 V617F mutation is not a common event in the pathogenesis ofAML M5, M6, and M7. (2017) (0)
Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth (2010) (0)
Transformation by the TEL/PDGFbetaR fusion protein does not require phosphatidylinositol 3-kinase or phospholipase C-gamma signaling (1997) (0)
TEL/PDGFβR Tyrosine Kinase Fusion Specifically Activates Myeloid Differentiation Programs, and Converts Lymphoid Progenitors into the Myeloid Lineage. (2004) (0)
leukemogenesis in mice for CBFB-MYH11 with D816 mutations cooperates with KIT (2014) (0)
p16INK4a Is a Key Downstream Mediator of the Deleterious Effects of FoxO Deficiency on Maintenance of the Hematopoietic Stem Cell Compartment. (2008) (0)
PKC412 Inhibits the ZNF198-FGFR1 Fusion Tyrosine Kinase and Is Efficacious in Treatment of t(8;13)(p11;q12) Associated Stem Cell Myeloproliferative Disease. (2004) (0)
High Resolution SNP Arrays and Correlation with Expression Arrays Identify Novel Genomic Aberrations and Potential Disease Genes in Polycythemia Vera and Other Myeloproliferative Disorders. (2006) (0)
Erratum to: Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis (Nature Genetics, (2018), 50, 8, (1072-1080), 10.1038/s41588-018-0157-1) (2018) (0)
A randomized trial of two doses of IL-3 in patients with MDS (1994) (0)
Mechanism of Oncogenesis by Leukemia-Associated Mutants of Shp2 (PTPN11). (2004) (0)
FLT3-ITD Cooperates with MOZ-TIF2 in Leukemogenesis in a Murine Bone Marrow Transplantation Model. (2006) (0)
Constitutively Active AKT Induces Myeloproliferative Disease, Acute Myeloid Leukemia, and T Cell Lymphoma despite Impaired Engraftment (2008) (0)
Abstract 34: Oncogenic tyrosine kinases phosphorylate and inhibit PKM2 to provide a metabolic advantage to tumor growth (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dwight Gary Gilliland?

Dwight Gary Gilliland is affiliated with the following schools: